STAGE IV URETHRAL CANCER AJCC V8

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This phase III trial is testing whether adding cabozantinib (a targeted therapy) to avelumab (an immunotherapy) as maintenance treatment works better than avelumab alone for people with metastatic urothelial cancer that has not progressed after initial chemotherapy. About 654 par…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…

This study tests whether adding propranolol (a blood pressure drug) to standard immunotherapy can help people with advanced bladder cancer. It involves 6 adults whose cancer has spread or cannot be removed. The main goal is to check safety and see how the combination affects the …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…